Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 8/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5688412 | 0.91 | LIPE (0.46) | LIPEGPR119ACACBACACABCHE | |
| SCHEMBL5931828 | 0.90 | LIPE (0.47) | LIPEGPR119ACACBACACAOPRM1 | |
| SCHEMBL5689014 | 0.89 | LIPE (0.44) | LIPEGPR119ACACBALDH1A1HTT | |
| SCHEMBL5690440 | 0.88 | LIPE (0.46) | LIPEGPR119ACACBACACABCHE | |
| SCHEMBL5688115 | 0.85 | LIPE (0.45) | LIPEGPR119ACACBACACABCHE | |
| SCHEMBL5687954 | 0.84 | EPHX2 (0.46) | GPR119ALDH1A1HTTEPHX2 | |
| SCHEMBL5688718 | 0.84 | LIPE (0.48) | LIPEGPR119ACACBACACABCHE | |
| SCHEMBL5687624 | 0.84 | ALDH1A1 (0.48) | GPR119ALDH1A1HTTEPHX2DRD2 | |
| SCHEMBL5688546 | 0.84 | LIPE (0.44) | LIPEGPR119ACACBACACABCHE | |
| SCHEMBL5688450 | 0.82 | LIPE (0.45) | LIPEGPR119ACACBACACABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | LIPE 1/4885GPR119 50/4885ACACB 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.